

NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE


Single Technology Appraisal

Epcoritamab with rituximab and lenalidomide for treating relapsed or refractory follicular lymphoma after 1 or more systemic treatments [ID6586]

Final Stakeholder List

Provisional Consultees	Provisional Commentators (no right to submit or appeal)
Company	 General All Wales Therapeutics and Toxicology Centre Allied Health Professionals Federation Board of Community Health Councils in Wales British National Formulary Care Quality Commission Department of Health - Northern Ireland Healthcare Improvement Scotland Medicines and Healthcare products Regulatory Agency National Association of Primary Care National Pharmacy Association NHS Confederation NHS Wales Joint Commissioning Committee Scottish Medicines Consortium Welsh Government
 South Asian Health Foundation Specialised Healthcare Alliance Tenovus Cancer Care Healthcare professional groups Association of Cancer Physicians British Geriatrics Society British Institute of Radiology British Oncology Pharmacy Association British Psychosocial Oncology Society British Society for Haematology British Society of Interventional Radiology British Transplantation Society 	 Comparator companies AbbVie (epcoritamab) Amarox (lenalidomide) Biocon Pharma (lenalidomide) Bristol Myers Squibb (lenalidomide) Celltrion Healthcare (rituximab) Dr Reddy's Laboratories (bendamustine, rituximab) Grindeks Kalceks UK (lenalidomide) Incyte Biosciences UK (tafasitamab) Mylan (lenalidomide) Pfizer (rituximab) Roche (obinutuzumab, rituximab) Sandoz (lenalidomide, rituximab)

Final stakeholder list for the evaluation of epcoritamab with rituximab and lenalidomide for treating relapsed or refractory follicular lymphoma after 1 or more systemic treatments [ID6586] Issue date: November 2025



Provisional Consultees Provisional Commentators (no right to submit or appeal) Cancer Research UK **Seacross Pharmaceuticals** NHS Blood and Transplant (bendamustine) Royal College of General Practitioners Sun Pharma (lenalidomide) Royal College of Nursing Teva UK (lenalidomide) Thornton & Ross (lenalidomide) Royal College of Pathologists Royal College of Physicians Relevant research groups Royal College of Radiologists Cochrane Haematology Group Royal Pharmaceutical Society Genomics England Royal Society of Medicine Institute of Cancer Research Society and College of Radiographers Leukaemia Busters **UK Clinical Pharmacy Association** Lymphoma Research Trust **UK Oncology Nursing Society** MRC Clinical Trials Unit National Institute for Health Research Department of Health and Social Care Associated Public Health groups **NHS** England **Public Health Wales UK Health Security Agency**

NICE is committed to promoting equality, eliminating unlawful discrimination and fostering good relations between people who share a protected characteristic and those who do not. Please let us know if we have missed any important organisations from the stakeholder list, and which organisations we should include that have a particular focus on relevant equality issues.

Definitions:


Consultee or commentator stakeholders are provisional until a signed Confidentiality Agreement & Undertaking form is submitted to NICE at the evaluation stage. Participating stakeholders will be listed on the project information page for the evaluation.

Consultees

Organisations that accept an invitation to participate in the evaluation; the company that markets the technology; national professional organisations; national patient organisations; the Department of Health and Social Care and relevant NHS organisations in England.

The company that markets the technology is invited to make an evidence submission, respond to consultations, nominate clinical experts and has the right to appeal against the Final Draft Guidance (FDG).

Final stakeholder list for the evaluation of epcoritamab with rituximab and lenalidomide for treating relapsed or refractory follicular lymphoma after 1 or more systemic treatments [ID6586] Issue date: November 2025



All non-company consultees are invited to submit a statement relevant to the group they are representing, respond to consultations, nominate clinical or patient experts and have the right to appeal against the Final Draft Guidance (FDG).

Commentators

Organisations that engage in the evaluation process but that are not asked to prepare an evidence submission or statement, are able to respond to consultations and they receive the FDG for information only, without right of appeal. These organisations are: companies that market comparator technologies; Healthcare Improvement Scotland; related research groups where appropriate (for example, the Medical Research Council [MRC]); other groups (for example, the NHS Confederation and the British National Formulary).

All non-company commentators are invited to nominate clinical or patient experts.